HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Bile pigment pharmacokinetics and absorption in the rat: therapeutic potential for enteral administration.

AbstractBACKGROUND AND PURPOSE:
Bilirubin and biliverdin possess antioxidant and anti-inflammatory properties and their exogenous administration protects against the effects of inflammation and trauma in experimental models. Despite the therapeutic potential of bile pigments, little is known about their in vivo parenteral or enteral absorption after exogenous administration. This study investigated the absorption and pharmacokinetics of bile pigments after i.v., i.p. and intraduodenal (i.d.) administration in addition to their metabolism and routes of excretion.
EXPERIMENTAL APPROACH:
Anaesthetized Wistar rats had their bile duct, jugular and portal veins cannulated. Bile pigments were infused and their circulating concentrations/biliary excretion were measured over 180 min. KEY RESULTS After i.v. administration of unconjugated bilirubin, biliverdin and bilirubin ditaurate, their plasma concentrations decreased exponentially over time. Subsequently, native and metabolized compounds appeared in the bile. When administered i.p., their absolute bioavailabilities equalled 14.0, 16.1 and 33.1%, respectively, and correspondingly 38, 28 and 34% of the same bile pigment doses were excreted in the bile. Administration of unconjugated bilirubin and bilirubin ditaurate i.d. increased their portal and systemic concentrations and their systemic bioavailability equalled 1.0 and 2.0%, respectively. Correspondingly, 2.7 and 4.6%, of the doses were excreted in the bile. Biliverdin was rapidly metabolized and these products were absorbed and excreted via the urine and bile.
CONCLUSIONS AND IMPLICATIONS:
Bile pigment absorption from the peritoneal and duodenal cavities demonstrate new routes of administration for the treatment of inflammatory and traumatic pathology. Oral biliverdin administration may lead to the production of active metabolite that protect from inflammation/complement activation.
AuthorsA C Bulmer, J S Coombes, J T Blanchfield, I Toth, R G Fassett, S M Taylor
JournalBritish journal of pharmacology (Br J Pharmacol) Vol. 164 Issue 7 Pg. 1857-70 (Dec 2011) ISSN: 1476-5381 [Electronic] England
PMID21486273 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.
Chemical References
  • Taurine
  • bilirubin ditaurine
  • Biliverdine
  • Bilirubin
Topics
  • Absorption
  • Animals
  • Bile (chemistry)
  • Bilirubin (administration & dosage, analogs & derivatives, pharmacokinetics)
  • Biliverdine (administration & dosage, pharmacokinetics)
  • Biological Availability
  • Duodenum (metabolism)
  • Gastrointestinal Contents
  • Injections
  • Intestinal Mucosa (metabolism)
  • Male
  • Peritoneal Cavity (physiology)
  • Rats
  • Rats, Wistar
  • Taurine (administration & dosage, analogs & derivatives, pharmacokinetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: